At the NHS Confederation Conference in Manchester, Simon Stevens the head of NHS England has announced the launch of a new programme to fast-track innovations from across the world to the NHS vanguard. For the first time, NHS will provide an explicit national compensation route which will accelerate the uptake on new medtech devices and apps for patients with condition including diabetes, asthma, heart conditions, sleep disorders, and other chronic health conditions. It also includes many other areas like obesity reduction and weight management, infertility and pregnancy, and common mental health disorders.
Clinicians and innovators will have an ease experience in getting uptake and spread across the NHS through this new funding route. Pricelist category of a new innovation and technology will eliminate the need of multiple local price debates. The use of an approved innovation guarantee automatic compensation whereas it allows NHS England to exchange national ‘bulk buy’ price discounts on behalf of hospitals, GPs and patients.
A new round of recruitment to the NHS Innovation Accelerator (NIA) programme was also announced by Stevens. It will supports developers to extend innovations further and faster across the health service. A rapid roll out of innovations to 68 hospitals which benefits over 3 million patients in a successful first year.
Some Examples of innovations sustained by the NIA programme are listed below.
Patients with Chronic Obstructive Pulmonary Disorder (COPD) can manage their condition themselves by using this app through their phone or tablet. It offers expert advice and education to patients on how to use their medication correctly and also give education on how to accomplish special exercise which will advance the lung function.
It is a mobile heart monitor which allow user to detect, monitor and manage heart arrhythmias and also captures electrocardiogram (ECG) recordings. In the UK around 100,000 people died annually due to Arrhythmias which cause sudden cardiac death. An estimation made by arrhythmia association shows 80% of these death could be avoided through better diagnosis. And also Incidents of atrial fibrillation can be detect by AliveCor.
It is used to monitor patients breathing electronically in intensive care which is a cuffed ventilation tube and inflating device. It helps to prevent bacteria leaking into lungs which can result in ventilator-associated pneumonia (VAP). VAP is a main cause of hospital-acquired mortality in Intensive Care. Annually, VAP detected on normal 10-20% patients with a 30% mortality rate. The cost of each VAP episode in the NHS is between £10k and £20k. Whenever PneuX is used NHS saves £700, which is shown from an estimation on New Cross, Birmingham.
According to Mr. Stevens the NHS has a satisfied track record of world firsts in medical innovation such as Hip replacements, IVF, vaccinations and organ transplants are just a few name. Often getting wide uptake has been slow and frustrating. So this time NHS is in under pressure and it’s time to clutch with practical new treatments and technologies.
Visit our blog page for more information on medical recruitment and latest update on healthcare system of the UK.